Skip to main content
Evotec SE logo

Evotec SE — Investor Relations & Filings

Ticker · EVT ISIN · DE0005664809 LEI · 529900F9KI6OYITO9B12 F Professional, scientific and technical activities
Open in API
Filings indexed 1,778 across all filing types
Latest filing 2014-01-03 Declaration of Voting R…
Country DE Germany
Listing F EVT

About Evotec SE

https://www.evotec.com/en

Evotec SE is a life science company focused on drug discovery and development in partnership with pharmaceutical and biotechnology firms. The company operates an integrated research and development value chain, utilizing proprietary technology platforms that incorporate AI-driven innovation and induced pluripotent stem cells (iPSC). Its expertise spans a wide range of therapeutic modalities, from small molecules to biotherapeutics. Through its Just – Evotec Biologics division, the company offers end-to-end solutions for the design, development, and manufacturing of biologic therapies, aiming to enhance their accessibility and affordability. Evotec employs flexible partnering models to accelerate the delivery of new treatments to patients with high efficiency and quality.

Recent filings

Filing Released Lang Actions
Declaration of Voting Results & Voting Rights Announcements 2014
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is explicitly titled 'Voting Rights Announcements' and contains multiple sections detailing 'Notification of voting rights pursuant to sec. 25 WpHG'. This type of filing reports changes in significant share ownership or voting power thresholds being crossed by an entity (Morgan Stanley and its subsidiaries). This directly corresponds to the definition of Major Shareholding Notification (MRQ), which covers changes in significant share ownership levels crossing thresholds. Although the title mentions 'Voting Rights Announcements', the content is a specific regulatory disclosure about voting rights thresholds being crossed, which aligns best with MRQ in the provided schema, as DVA is for voting results, not ongoing ownership changes.
2014-01-03 English
Declaration of Voting Results & Voting Rights Announcements 2014
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is explicitly titled 'Voting Rights Announcements' and details notifications received from various Morgan Stanley entities regarding their voting rights falling below the 3% threshold in Evotec AG, as required by § 26 paragraph. 1 WpHG (German Securities Trading Act). This directly corresponds to the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA). Although it is a regulatory announcement, DVA is a more specific category than the general RNS.
2014-01-03 English
Evotec AG: Release according to Article 26a of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a short announcement (1367 characters) titled 'Total Voting Rights Announcement' and references Article 26a of the WpHG. It explicitly states the total number of voting rights as of December 31, 2013, following the exercise of stock options. This type of announcement, detailing changes in the total number of shares/voting rights, most closely aligns with 'Share Issue/Capital Change' (SHA) or potentially a general regulatory filing (RNS). However, since it specifically reports on the total voting rights count, SHA is the most precise fit among the defined categories, as changes in voting rights stem from capital structure changes like option exercises. It is not a full report, an earnings release, or a director's dealing.
2013-12-31 English
Evotec and Yale University to collaborate on cancer therapy
Regulatory Filings Classification · 100% confidence The document is a press release dated December 17, 2013, announcing a research collaboration between Evotec AG and Yale University regarding cancer therapy. It uses keywords like 'DGAP-News', 'Corporate News', and discusses a new alliance. This type of announcement, detailing strategic partnerships, research milestones, or business developments that are not standard financial reports (10-K, IR, ER) or mandatory regulatory filings like insider trades (DIRS) or capital changes (SHA), typically falls under general regulatory announcements or press releases. Since it is a specific announcement of a strategic business development and not a mandatory financial filing, and it doesn't fit other specific categories like M&A (TAR) or Director changes (MANG), the most appropriate general category for a non-standard, non-financial corporate news release distributed via a service like DGAP is 'Regulatory Filings' (RNS), which serves as the fallback for miscellaneous announcements.
2013-12-17 English
Evotec AG: Results of pre-clinical studies lead to reduction in revenues, nevertheless profitable and more than EUR 90 m cash for 2013 confirmed
Regulatory Filings Classification · 99% confidence The document is titled 'Ad-hoc' and dated 13 December 2013. It explicitly states that Evotec AG is 'adjusting its guidance regarding Group revenues' for the fiscal year 2013, detailing a reduction in expected revenues due to a failed milestone trigger and potential impairment charges. This type of announcement, which provides key financial highlights and guidance changes outside of a full quarterly or annual report, aligns best with an Earnings Release (ER). Although it is an 'Ad hoc' announcement, the content is focused on revised financial performance expectations, making ER the most specific fit among the provided options, rather than the general Regulatory Filing (RNS). The document length is short (2747 chars), but its primary function is communicating revised financial results/outlook, not just announcing that a report is available.
2013-12-13 English
Evotec receives pre-clinical milestone as part of its discovery alliance with Boehringer Ingelheim
Regulatory Filings Classification · 99% confidence The document is a press release dated December 10, 2013, announcing that Evotec AG achieved a pre-clinical milestone in its discovery alliance with Boehringer Ingelheim, triggering a revenue of EUR 4.0 million. It contains standard press release formatting, including headers like 'DGAP-News' and 'Corporate News', and concludes with contact information and disclaimers typical of such announcements. This type of announcement, detailing a specific business event (milestone payment) that is not a full financial report (10-K, IR), earnings release (ER), or dividend notice (DIV), fits best under the general 'Regulatory Filings' category (RNS) as a corporate news item disseminated via a service like DGAP, or potentially a Capital/Financing Update (CAP) due to the revenue recognition, but RNS is the most appropriate general regulatory announcement fallback for non-standard news.
2013-12-10 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.